116 related articles for article (PubMed ID: 34520770)
21. [Abnormal expression of beta-catenin and E-cadherin in Her2-positive breast cancer and its implications].
Niu LG; He JJ; Wang K; Zhang W; Zhou C
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Nov; 29(11):2237-40. PubMed ID: 19923077
[TBL] [Abstract][Full Text] [Related]
22. A diverse induction of apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells.
Atmaca H; Bozkurt E; Uzunoglu S; Uslu R; Karaca B
Toxicol Lett; 2013 Aug; 221(2):128-36. PubMed ID: 23792433
[TBL] [Abstract][Full Text] [Related]
23. Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner.
Zhu M; Shi X; Gong Z; Su Q; Yu R; Wang B; Yang T; Dai B; Zhan Y; Zhang D; Zhang Y
Pharmacol Res; 2020 Aug; 158():104868. PubMed ID: 32407961
[TBL] [Abstract][Full Text] [Related]
24. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA
Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689
[TBL] [Abstract][Full Text] [Related]
25. HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells.
Cheng JC; Qiu X; Chang HM; Leung PC
Biochem Biophys Res Commun; 2013 Apr; 434(1):81-6. PubMed ID: 23542467
[TBL] [Abstract][Full Text] [Related]
26. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
27. Apigenin induces caspase-dependent apoptosis by inhibiting signal transducer and activator of transcription 3 signaling in HER2-overexpressing SKBR3 breast cancer cells.
Seo HS; Ku JM; Choi HS; Woo JK; Jang BH; Go H; Shin YC; Ko SG
Mol Med Rep; 2015 Aug; 12(2):2977-84. PubMed ID: 25936427
[TBL] [Abstract][Full Text] [Related]
28. RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells.
Brusgard JL; Choe M; Chumsri S; Renoud K; MacKerell AD; Sudol M; Passaniti A
Oncotarget; 2015 Sep; 6(29):28132-50. PubMed ID: 26320173
[TBL] [Abstract][Full Text] [Related]
29. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
30. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor.
Noren NK; Yang NY; Silldorff M; Mutyala R; Pasquale EB
Biochem J; 2009 Aug; 422(3):433-42. PubMed ID: 19552627
[TBL] [Abstract][Full Text] [Related]
31. Ambrosin sesquiterpene lactone exerts selective and potent anticancer effects in drug-resistant human breast cancer cells (MDA-MB-231) through mitochondrial mediated apoptosis, ROS generation and targeting Akt/β-Catenin signaling pathway.
Fan S; Cui Y; Hu Z; Wang W; Jiang W; Xu H
J BUON; 2020; 25(5):2221-2227. PubMed ID: 33277839
[TBL] [Abstract][Full Text] [Related]
32. Novel Nitrogen-Based Chalcone Analogs Provoke Substantial Apoptosis in HER2-Positive Human Breast Cancer Cells via JNK and ERK1/ERK2 Signaling Pathways.
Rizeq B; Gupta I; Kheraldine H; Elkhalifa D; Al-Farsi HF; Moustafa AA; Khalil A
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502529
[TBL] [Abstract][Full Text] [Related]
33. The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: Induction of cancer cell death by targeting apoptotic and metabolic signaling pathways.
Guerram M; Jiang ZZ; Yousef BA; Hamdi AM; Hassan HM; Yuan ZQ; Luo HW; Zhu X; Zhang LY
Oncotarget; 2015 Sep; 6(26):21865-77. PubMed ID: 26068969
[TBL] [Abstract][Full Text] [Related]
34. AK4 Promotes the Progression of HER2-Positive Breast Cancer by Facilitating Cell Proliferation and Invasion.
Zhang J; Yin YT; Wu CH; Qiu RL; Jiang WJ; Deng XG; Li ZX
Dis Markers; 2019; 2019():8186091. PubMed ID: 31827645
[TBL] [Abstract][Full Text] [Related]
35. Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes.
Papanikolaou V; Stefanou N; Dubos S; Papathanasiou I; Palianopoulou M; Valiakou V; Tsezou A
Cell Oncol (Dordr); 2015 Apr; 38(2):155-64. PubMed ID: 25539992
[TBL] [Abstract][Full Text] [Related]
36. Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin.
Sun SH; Huang HC; Huang C; Lin JK
Eur J Pharmacol; 2012 Sep; 690(1-3):22-30. PubMed ID: 22705896
[TBL] [Abstract][Full Text] [Related]
37. The anti-malarial drug artesunate causes cell cycle arrest and apoptosis of triple-negative MDA-MB-468 and HER2-enriched SK-BR-3 breast cancer cells.
Greenshields AL; Fernando W; Hoskin DW
Exp Mol Pathol; 2019 Apr; 107():10-22. PubMed ID: 30660598
[TBL] [Abstract][Full Text] [Related]
38. Α-eleostearic acid inhibits growth and induces apoptosis in breast cancer cells via HER2/HER3 signaling.
Zhuo RJ; Wang F; Zhang XH; Zhang JJ; Xu J; Dong W; Zou ZQ
Mol Med Rep; 2014 Mar; 9(3):993-8. PubMed ID: 24425042
[TBL] [Abstract][Full Text] [Related]
39. The role of EphB4 and IGF-IR expression in breast cancer cells.
Huang G; Li M
Int J Clin Exp Pathol; 2015; 8(5):5997-6004. PubMed ID: 26191333
[TBL] [Abstract][Full Text] [Related]
40. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
